Heart Failure and Chronic Kidney Disease Manifestation and Mortality Risk -Associations in Type 2 Diabetes: A Large Multinational Cohort Study

被引:0
作者
Birkeland, K. I. [1 ,2 ]
Bodegard, J. [3 ]
Eriksson, J. W. [4 ]
Norhammar, A. [5 ,6 ]
Haller, H. [7 ]
Linssen, G. C. M. [8 ]
Banerjee, A. [9 ,10 ]
Thuresson, M. [11 ]
Okami, S. [12 ]
Garal-Pantaler, E. [13 ]
Overbeek, J. [14 ]
Mamza, J. B. [15 ]
Zhang, R. [15 ]
Yajima, T. [12 ]
Komuro, I. [16 ]
Kadowaki, T. [17 ,18 ]
机构
[1] Univ Klinikum Oslo, Oslo, Norway
[2] Univ Oslo, Oslo, Norway
[3] AstraZeneca, Oslo, Norway
[4] Uppsala Univ, Klin Diabet & Stoffwechsel, Abt Med Wissensch, Uppsala, Sweden
[5] Karolinska Inst, Kardiol Fachbereich Med Solna, Stockholm, Sweden
[6] Capio St Gorans Krankenhaus, Stockholm, Sweden
[7] Hannover Med Sch, Nephrol Abt, Hannover, Germany
[8] Abt Kardiol Krankenhausgruppe Twente, Hengelo, Niederlande
[9] Coll Univ London, Inst Gesundheitsinformat, London, England
[10] Krankenhauser Coll Univ London, Abt Kardiol, London, England
[11] Statisticon AB, Uppsala, Sweden
[12] AstraZeneca, Osaka, Japan
[13] Team Gesundheit GmbH, Essen, Germany
[14] PHARMO Inst Erforschung Arzneimittelwirkungen, Utrecht, Netherlands
[15] AstraZeneca, Luton, Beds, England
[16] Med Hsch Univ Tokio, Abt Kardiovask Med, Tokyo, Japan
[17] Hsch Med Univ Tokio, Abt Pravent Diabet & Lebensstilbedingten Erkrank, Tokyo, Japan
[18] Mizonokuchi Krankenhaus Teikyo Univ, Abt Metab & Ernahrung, Teikyo, Kanagawa, Japan
来源
DIABETES STOFFWECHSEL UND HERZ | 2021年 / 30卷 / 01期
关键词
diabetic nephropathy; heart failure; macrovascular disease; observational study; type; 2; diabetes; SGLT2; inhibitor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. Methods: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD-free status. Results: Of 1 177 896 patients with T2D, 772 336 (66 %) were CVRD-free and followed for a mean of 4.5 years. A total of 137081 patients (18 %) developed a first CVRD manifestation, represented by CKD (36 %), HF (24 %), stroke (16 %), MI (14 %) and PAD (10 %). HF or CKD was associated with increased cardiovascular and allcause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75 - 2.33) and HR 2.05 (95 % CI 1.82 - 2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all-cause mortality risk: HRs 3.91 (95 % CI 3.02 - 5.07) and 3.14 (95 % CI 2.90 - 3.40), respectively. Conclusion: In a large multinational study of > 750 000 CVRD-free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 58 条
  • [31] Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy
    Lebeche, Djamel
    Davidoff, Amy J.
    Hajjar, Roger J.
    [J]. NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (11): : 715 - 724
  • [32] Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes
    Levelt, Eylem
    Mahmod, Masliza
    Piechnik, Stefan K.
    Ariga, Rina
    Francis, Jane M.
    Rodgers, Christopher T.
    Clarke, William T.
    Sabharwal, Nikant
    Schneider, Jurgen E.
    Karamitsos, Theodoros D.
    Clarke, Kieran
    Rider, Oliver J.
    Neubauer, Stefan
    [J]. DIABETES, 2016, 65 (01) : 44 - 52
  • [33] Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
    Mahaffey, Kenneth W.
    Jardine, Meg J.
    Bompoint, Severine
    Cannon, Christopher P.
    Neal, Bruce
    Heerspink, Hiddo J. L.
    Charytan, David M.
    Edwards, Robert
    Agarwal, Rajiv
    Bakris, George
    Bull, Scott
    Capuano, George
    de Zeeuw, Dick
    Greene, Tom
    Levin, Adeera
    Pollock, Carol
    Sun, Tao
    Wheeler, David C.
    Yavin, Yshai
    Zhang, Hong
    Zinman, Bernard
    Rosenthal, Norman
    Brenner, Barry M.
    Perkovic, Vlado
    Ahuad Guerrero, Rodolfo Andres
    Aizenberg, Diego
    Pablo Albisu, Juan
    Alvarisqueta, Andres
    Bartolacci, Ines
    Alberto Berli, Mario
    Bordonava, Anselmo
    Calella, Pedro
    Cecilia Cantero, Maria
    Rodolfo Cartasegna, Luis
    Cercos, Esteban
    Cecilia Coloma, Gabriela
    Colombo, Hugo
    Commendatore, Victor
    Cuadrado, Jesus
    Alberto Cuneo, Carlos
    Maria Cusumano, Ana
    Guillermo Douthat, Walter
    Dario Dran, Ricardo
    Farias, Eduardo
    Florencia Fernandez, Maria
    Finkelstein, Hernan
    Fragale, Guillermo
    Osvaldo Fretes, Jose
    Horacio Garcia, Nestor
    Gastaldi, Anibal
    [J]. CIRCULATION, 2019, 140 (09) : 739 - 750
  • [34] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    McMurray, J. J. V.
    Solomon, S. D.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Ponikowski, P.
    Sabatine, M. S.
    Anand, I. S.
    Belohlavek, J.
    Bohm, M.
    Chiang, C. -E.
    Chopra, V. K.
    de Boer, R. A.
    Desai, A. S.
    Diez, M.
    Drozdz, J.
    Dukat, A.
    Ge, J.
    Howlett, J. G.
    Katova, T.
    Kitakaze, M.
    Ljungman, C. E. A.
    Merkely, B.
    Nicolau, J. C.
    O'Meara, E.
    Petrie, M. C.
    Vinh, P. N.
    Schou, M.
    Tereshchenko, S.
    Verma, S.
    Held, C.
    DeMets, D. L.
    Docherty, K. F.
    Jhund, P. S.
    Bengtsson, O.
    Sjostrand, M.
    Langkilde, A. -M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 1995 - 2008
  • [35] Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Cahn, Avivit
    Rozenberg, Aliza
    Yanuv, Ilan
    Goodrich, Erica L.
    Murphy, Sabina A.
    Heerspink, Hiddo J. L.
    Zelniker, Thomas A.
    Dwyer, Jamie P.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Kato, Eri T.
    Gause-Nilson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (08) : 606 - 617
  • [36] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Erondu, Ngozi
    Shaw, Wayne
    Law, Gordon
    Desai, Mehul
    Matthews, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) : 644 - 657
  • [37] The incidence of congestive heart failure in type 2 diabetes
    Nichols, GA
    Gullion, CM
    Koro, CE
    Ephross, SA
    Brown, JB
    [J]. DIABETES CARE, 2004, 27 (08) : 1879 - 1884
  • [38] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
    Perkovic, V.
    Jardine, M. J.
    Neal, B.
    Bompoint, S.
    Heerspink, H. J. L.
    Charytan, D. M.
    Edwards, R.
    Agarwal, R.
    Bakris, G.
    Bull, S.
    Cannon, C. P.
    Capuano, G.
    Chu, P. -L.
    De Zeeuw, D.
    Greene, T.
    Levin, A.
    Pollock, C.
    Wheeler, D. C.
    Yavin, Y.
    Zhang, H.
    Zinman, B.
    Meininger, G.
    Brenner, B. M.
    Mahaffey, K. W.
    McGuire, Darren K.
    Holman, Rury
    Home, Philip
    Scharfstein, Dan
    Parfrey, Patrick
    Shahinfar, Shahnaz
    August, Phyllis
    Chang, Tara
    Sinha, Arjun D.
    Januzzi, James
    Kolansky, Daniel
    Amerena, John
    Hillis, Graham
    Gorelick, Philip
    Kissela, Brett
    Kasner, Scott
    Lindley, Richard
    Fulcher, Greg
    Ounadjela, Souhila
    Hufert, Karina
    von Ingersleben, Gabriele
    Gaglia, Jason
    Harris, Ronald
    Hudson, Margo
    Turchin, Alexander
    Cheifetz, Adam
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) : 2295 - 2306
  • [39] Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
    Persson, Frederik
    Nystrom, Thomas
    Jorgensen, Marit E.
    Carstensen, Bendix
    Gulseth, Hanne L.
    Thuresson, Marcus
    Fenici, Peter
    Nathanson, David
    Eriksson, Jan W.
    Norhammar, Anna
    Bodegard, Johan
    Birkeland, Kare I.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (02) : 344 - 351
  • [40] Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies A Scientific Statement From the American Heart Association
    Rangaswami, Janani
    Bhalla, Vivek
    Blair, John E. A.
    Chang, Tara, I
    Costa, Salvatore
    Lentine, Krista L.
    Lerma, Edgar, V
    Mezue, Kenechukwu
    Molitch, Mark
    Mullens, Wilfried
    Ronco, Claudio
    Tang, W. H. Wilson
    McCullough, Peter A.
    [J]. CIRCULATION, 2019, 139 (16) : E840 - E878